SG11202010528XA - Combinations for treating cancer - Google Patents

Combinations for treating cancer

Info

Publication number
SG11202010528XA
SG11202010528XA SG11202010528XA SG11202010528XA SG11202010528XA SG 11202010528X A SG11202010528X A SG 11202010528XA SG 11202010528X A SG11202010528X A SG 11202010528XA SG 11202010528X A SG11202010528X A SG 11202010528XA SG 11202010528X A SG11202010528X A SG 11202010528XA
Authority
SG
Singapore
Prior art keywords
combinations
treating cancer
cancer
treating
Prior art date
Application number
SG11202010528XA
Other languages
English (en)
Inventor
Scott Boiko
Justin Cidado
Lisa Drew
Theresa Proia
Martin Maryann San
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11202010528XA publication Critical patent/SG11202010528XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202010528XA 2018-04-30 2019-04-29 Combinations for treating cancer SG11202010528XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862664356P 2018-04-30 2018-04-30
PCT/IB2019/053491 WO2019211721A1 (en) 2018-04-30 2019-04-29 Combinations for treating cancer

Publications (1)

Publication Number Publication Date
SG11202010528XA true SG11202010528XA (en) 2020-11-27

Family

ID=66794041

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010528XA SG11202010528XA (en) 2018-04-30 2019-04-29 Combinations for treating cancer

Country Status (14)

Country Link
US (1) US20210030718A1 (zh)
EP (1) EP3787620A1 (zh)
JP (1) JP2021522246A (zh)
KR (1) KR20210005182A (zh)
CN (1) CN112040944A (zh)
AU (1) AU2019263026B2 (zh)
BR (1) BR112020022020A2 (zh)
CA (1) CA3097486A1 (zh)
EA (1) EA202092540A1 (zh)
MA (1) MA52499A (zh)
MX (1) MX2020011453A (zh)
SG (1) SG11202010528XA (zh)
TW (1) TW202014184A (zh)
WO (1) WO2019211721A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021089419A1 (en) * 2019-11-04 2021-05-14 Astrazeneca Ab Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
WO2021126316A1 (en) * 2019-12-18 2021-06-24 Zeno Management, Inc. Macrocyclic compounds
CA3222752A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
TW202315637A (zh) 2021-06-11 2023-04-16 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037644B1 (ru) 2011-07-19 2021-04-26 Мерк Шарп и Доум Б.В. СПОСОБ ПОЛУЧЕНИЯ Btk-ИНГИБИТОРА
MX2017001656A (es) * 2014-08-08 2017-07-24 Pharmacyclics Llc Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
EP3445767B1 (en) 2016-04-22 2020-02-19 Astrazeneca AB Macrocyclic mcl1 inhibitors for treating cancer
CN107056786B (zh) * 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法

Also Published As

Publication number Publication date
AU2019263026B2 (en) 2022-06-30
JP2021522246A (ja) 2021-08-30
CN112040944A (zh) 2020-12-04
MA52499A (fr) 2021-04-14
WO2019211721A1 (en) 2019-11-07
EA202092540A1 (ru) 2021-03-17
MX2020011453A (es) 2020-12-07
AU2019263026A1 (en) 2020-12-17
EP3787620A1 (en) 2021-03-10
US20210030718A1 (en) 2021-02-04
BR112020022020A2 (pt) 2021-02-02
TW202014184A (zh) 2020-04-16
CA3097486A1 (en) 2019-11-07
KR20210005182A (ko) 2021-01-13

Similar Documents

Publication Publication Date Title
IL270720A (en) Combination of treatments for cancer treatment
EP3641770A4 (en) METHOD OF TREATMENT OF CANCER
IL260443B (en) Combinations of anti-egfr for cancer treatment
IL260444B (en) Anti-her2 combinations for cancer treatment
IL255060A0 (en) Combined treatment for cancer
IL282663A (en) BT1718 for use in cancer treatment
IL273395A (en) Combined therapies for cancer treatment
EP3678663A4 (en) POLYTHERAPY FOR CANCER TREATMENT
GB201903546D0 (en) Cancer treatment
PT3576740T (pt) Tratamento de cancro
IL287907A (en) Cancer treatment methods
IL277861A (en) Antibodies specific to AXL for cancer treatment
SG11202010528XA (en) Combinations for treating cancer
EP3892282A4 (en) COMBINATIONS FOR TREATING CANCER
IL268416A (en) Pharmaceutical combinations for cancer treatment
GB201820660D0 (en) Cancer treatments
IL282093A (en) Combination therapy for cancer
GB201706451D0 (en) Cancer treatment
IL287652A (en) Cancer treatment
IL268463A (en) Cancer treatment
IL285466A (en) Cancer treatment
GB201800733D0 (en) Cancer
IL274626A (en) Cancer treatment
EP3894561A4 (en) CANCER TREATMENT METHODS
GB201909468D0 (en) Compounds for treating cancer